CE / CME
In this certified on-demand webcast, experts review the unmet needs in metastatic castration-resistant prostate cancer, emphasize the importance and timing of germline and somatic biomarker testing, and discuss how PARP inhibitors and PARP inhibitor combinations can be optimally integrated into clinical practice.
Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits
Registered Nurses: 1.50 Nursing contact hour
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians: maximum of 1.50 AMA PRA Category 1 Credits
Released: April 01, 2026
Expiration: September 30, 2026
Share
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.
Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
AstraZeneca
Merck & Co., Inc., Rahway, NJ, USA
Clinical Care Options, LLC dba Decera Clinical Education
This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.
This activity aims to enhance learners’ knowledge and competence in selecting, sequencing, and managing PARP inhibitor-based therapies for mPC through guideline-concordant testing, informed clinical decision-making based on biomarker results, and proactive toxicity mitigation strategies—ultimately improving patient outcomes.
Upon completion of this activity, participants should be able to:
Incorporate genetic testing workflows in concordance with guideline recommendations for all HRR mutations to identify patients who may benefit from PARP inhibitor–based therapy
Evaluate efficacy, treatment sequencing, and subgroup data from recent trials of PARPi combinations in mPC, and assess their implications across BRCA and non-BRCA HRR mutation populations
Formulate patient care plans with PARP inhibitor-based combination regimens for the treatment of patients with mPC, taking into account recent guideline updates for sequencing, expert recommendations, and recent data, including patient subgroup data
Employ multidisciplinary strategies for ongoing therapy management to mitigate and manage adverse events associated with PARPi combination regimens, thereby improving quality of life, adherence, and outcomes in patients with mPC
Integrate strategies to identify and address barriers to appropriate genetic and biomarker testing for patients with mPC, including testing workflows and the role of the multidisciplinary care team
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Primary AuthorWassim Abida, MD, PhD: consultant/advisor/speaker: Aptitude Health, AstraZeneca, BoundlessBio, Duality, IDEOlogy, Tolmar.
Nabil Adra, MD, MS: consultant/advisor/speaker: Merck.
Neeraj Agarwal, MD, FASCO, has no relevant financial relationships to disclose.
Kristine Peregrino Lacuna, MD: consultant/advisor/speaker: Bayer.
NCCN and Decera Staff Disclosures
None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 01, 2026, through September 30, 2026:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. This program offers 1.5 pharmacotherapeutic contact hours for nurses.
Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-030-H01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until September 24, 2026. PAs should only claim credit commensurate with the extent of their participation.